Global Information
회사소개 | 문의 | 비교리스트

세계의 진행성 핵상성 마비(PSP) 치료 시장 - 치료 유형별(치유적 요법, 완화요법/대증요법), 주요 지역별(미국, 영국, 독일, 프랑스, 이탈리아, 스페인) : 업계 동향과 예측(2021-2030년)

Progressive Supranuclear Palsy (PSP) Therapies Market by Type of Treatment (Curative and Palliative / Symptomatic), and Key Geographical Regions (US, UK, Germany, France, Italy and Spain): Industry Trends and Global Forecasts, 2021-2030

리서치사 Roots Analysis
발행일 2021년 08월 상품코드 1041938
페이지 정보 영문 106 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 5,499 ₩ 7,006,000 PDF (Single User License)
US $ 7,999 ₩ 10,192,000 PDF (Site License)
US $ 15,999 ₩ 20,385,000 PDF (Enterprise License)


세계의 진행성 핵상성 마비(PSP) 치료 시장 - 치료 유형별(치유적 요법, 완화요법/대증요법), 주요 지역별(미국, 영국, 독일, 프랑스, 이탈리아, 스페인) : 업계 동향과 예측(2021-2030년) Progressive Supranuclear Palsy (PSP) Therapies Market by Type of Treatment (Curative and Palliative / Symptomatic), and Key Geographical Regions (US, UK, Germany, France, Italy and Spain): Industry Trends and Global Forecasts, 2021-2030
발행일 : 2021년 08월 페이지 정보 : 영문 106 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

개요

세계의 진행성 핵상성 마비(PSP: Curative) 치료제 시장을 분석했으며, 현재의 임상시험 진행 상황, 현재 개발 중인 치료제 개요, 주요 기업 개요, 업계 주요 투자자, 업계 KOL(Key Opinion Leader) 개요, 주요 사업 제휴 및 협력 동향, 향후 시장 동향에 대한 주요 영향요인, 현재 및 향후 시장 기회(부문별), 시장 규모 동향 전망(향후 10년간) 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

제2장 개요

제3장 서론

제4장 파이프라인 분석

  • 분석 개요
  • 진행성 핵상성 마비 : 개발 파이프라인
  • 진행성 핵상성 마비 : 파이프라인 분석
    • 개발 단계별 분석
    • 의약품 클래스별 분석
    • 투여 경로별 분석
    • 작용기전별 분석
  • 진행성 핵상성 마비 : 개발 기업
    • 설립년도별 분석
    • 기업 규모별 분석
    • 입지별 분석

제5장 기업 개요

제6장 KOL(Key Opinion Leader) 분석

제7장 사업 제휴 및 협력

제8장 펀딩 및 투자 분석

제9장 임상시험 분석

제10장 시장 규모 및 기회 분석

제11장 경영진 인사이트

제12장 결론

제13장 부록 1 : 표 형식 데이터

제14장 부록 2 : 기업 및 조직 리스트

LSH 22.01.05

Overview

The "Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Progressive Supranuclear Palsy.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product's mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Progressive Supranuclear Palsy, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2031.

Scope of the Report

  • A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and mechanism of action across the complete product development cycle, including all clinical and nonclinical stages.
  • Detailed profiles of the players that are engaged in the development of drug products / therapies for Progressive Supranuclear Palsy, featuring overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and an informed future outlook.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population, route of administration, treatment type and dosing frequency, and target patient population, expected launch date and size of developer company.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
  • An analysis of the partnerships that have been established in the domain, over the last five years, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status, and trial focus, highlighting leading sponsors, type of organization, and regional distribution of trials. In addition, it features an insightful clinical end-points analysis.

Key Questions Answered:

  • What are the prevalent R&D trends related to Progressive Supranuclear Palsy?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the contributions of big pharma players in this field?
  • What are the key geographies where research on Progressive Supranuclear Palsy is being conducted?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders / experts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Pipeline Review

  • 4.1. Chapter Overview
  • 4.2. Progressive Supranuclear Palsy: Development Pipeline
  • 4.3. Progressive Supranuclear Palsy: Pipeline Analysis
    • 4.3.1. Analysis by Phase of Development
    • 4.3.2. Analysis by Drug Class
    • 4.3.3. Analysis by Route of Administration
    • 4.3.4. Analysis by Mechanism of Action
  • 4.4. Progressive Supranuclear Palsy: Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size
    • 4.4.3. Analysis by Geographical Location

5. Company Profiles

6. KOL Analysis

7. Partnerships and Collaborations

8. Funding and Investment Analysis

9. Clinical Trials Analysis

10. Market Sizing and Opportunity Analysis

11. Executive Insights

12. Concluding Remarks

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

Back to Top
전화 문의
F A Q